Cite
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR
MLA
Emilio Francesco Giunta, et al. “Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR.” Cancers, vol. 14, no. 13, June 2022, p. 3053. EBSCOhost, https://doi.org/10.3390/cancers14133053.
APA
Emilio Francesco Giunta, Vincenzo De Falco, Pietro Paolo Vitiello, Luigi Pio Guerrera, Gabriella Suarato, Rossella Napolitano, Alessandra Perrone, Giuseppe Argenziano, Renato Franco, Michele Caraglia, Erika Martinelli, Davide Ciardiello, Fortunato Ciardiello, Stefania Napolitano, & Teresa Troiani. (2022). Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. Cancers, 14(13), 3053. https://doi.org/10.3390/cancers14133053
Chicago
Emilio Francesco Giunta, Vincenzo De Falco, Pietro Paolo Vitiello, Luigi Pio Guerrera, Gabriella Suarato, Rossella Napolitano, Alessandra Perrone, et al. 2022. “Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR.” Cancers 14 (13): 3053. doi:10.3390/cancers14133053.